Study on how Stargardt eye conditions progress in children and adults
Part of Eyes & vision, Genetic & congenital clinical trials.
This study observes how Stargardt disease and similar eye conditions change over time in children and adults. It aims to learn more about the disease progression to help develop future treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a doctor's diagnosis of Stargardt disease or a similar macular dystrophy, confirmed by genetic testing.
- Your eyesight must be between 20/500 and 20/40 (moderate to severe vision loss).
- You must be able to complete all study visits and tests.
- You cannot have other serious eye diseases like glaucoma, diabetic retinopathy, or a history of certain eye surgeries.
- You cannot be taking certain medications that are toxic to the eyes, like hydroxychloroquine or tamoxifen.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests how well ALK-001 is tolerated and whether it can slow or improve vision-related changes in people with Stargardt disease. It mainly looks at safety (tolerability) and signs in the eye over about 24 months.
This trial tests a new drug, ALK-001, to see if it can slow down vision loss from Stargardt disease. It is for people who have a confirmed genetic diagnosis and are between 8 and 45 years old.
This trial tests a new gene therapy, AAVB-039, for people with Stargardt disease caused by a specific gene mutation. The treatment is given during eye surgery and aims to slow or stop vision loss.
This study tests a single injection of ASP2020 in the eye to see if it is safe and if it can help improve vision for people with Stargardt disease or similar inherited eye conditions.
This study follows people with Stargardt disease (a genetic eye condition that causes vision loss) over time. It aims to learn more about how the disease progresses and does not test any treatment.
This study tests a new way to measure vision, called MLSDT, in people with normal sight or vision loss from Stargardt disease or geographic atrophy (a type of advanced age-related macular degeneration). Results will help doctors better understand how well patients can see.
Hear when a new Stargardt Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.